This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. See our full medical disclaimer for details.

This article contains affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you. See our full affiliate disclosure for details.

Mounjaro vs Zepbound: Same Drug, Different Approvals [2026]

What Is Tirzepatide and Why Does It Have Two Names?

Here's the part that confuses almost everyone. Mounjaro and Zepbound are not similar drugs. They are not related drugs. They are the identical drug. Every vial of Mounjaro and every vial of Zepbound contains tirzepatide — same chemical structure, same manufacturing process, same Eli Lilly facility. If you ran them through a mass spectrometer, you'd get the same readout.

So why two brand names?

The answer is regulatory. The FDA approves drugs for specific indications — specific conditions a drug is proven to treat. A pharmaceutical company must run separate clinical trial programs for each indication and submit separate applications. Eli Lilly ran one set of trials (the SURPASS program) proving tirzepatide works for type 2 diabetes, and a separate set (the SURMOUNT program) proving it works for chronic weight management. Each trial program led to a separate FDA approval, and each approval got its own brand name.

This isn't unusual in the pharmaceutical industry. Semaglutide follows the same pattern: Ozempic is semaglutide approved for diabetes, and Wegovy is semaglutide approved for weight loss. Bupropion is sold as Wellbutrin for depression and Zyban for smoking cessation. Same molecule, different label, different billing code.

The Dual-Action Mechanism

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its kind approved by the FDA. That dual mechanism is what sets it apart from semaglutide-based medications, which only target GLP-1 receptors.

Here's how it works:

GLP-1 receptor activation slows gastric emptying, reduces appetite signaling in the brain, and stimulates insulin secretion when blood sugar is elevated. This is the same pathway that Ozempic and Wegovy use.
GIP receptor activation enhances the insulin response further, improves fat metabolism, and appears to amplify the weight-loss effects of GLP-1 stimulation. GIP signaling may also reduce fat accumulation in the liver and improve lipid profiles.

The combination of these two pathways is believed to explain why tirzepatide produces greater weight loss and comparable or superior blood sugar control versus semaglutide in head-to-head trials. The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, showed tirzepatide achieved 20.2% average body weight reduction compared to 13.7% for semaglutide over 72 weeks — a statistically significant 6.5 percentage point advantage (P<0.001).

For a deeper dive into how these two molecules compare, see our semaglutide vs tirzepatide comparison.

Side-by-Side Comparison: Mounjaro vs Zepbound

Before we go deeper, here's a quick reference table covering every meaningful difference (and similarity) between these two medications.

Feature	Mounjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide
Manufacturer	Eli Lilly	Eli Lilly
FDA approval date	May 2022	November 2023
Approved indication	Type 2 diabetes (adjunct to diet and exercise)	Chronic weight management (BMI ≥30, or ≥27 with weight-related comorbidity); Obstructive sleep apnea
Available doses	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Delivery method	Weekly subcutaneous injection (pre-filled pen)	Weekly subcutaneous injection (pre-filled pen)
List price (2026)	~$1,023/month	~$1,059/month
Medicare coverage	Yes (Part D for diabetes)	No (weight-loss drugs excluded)
Commercial insurance	Widely covered for type 2 diabetes	Limited — many plans exclude weight-loss drugs
Eli Lilly savings card	Yes — eligible patients may pay as low as $25/month	Yes — eligible patients may pay as low as $25/month
Side effects	Nausea, diarrhea, vomiting, constipation, abdominal pain, injection site reactions	Identical (same drug)
Black box warning	Thyroid C-cell tumors (rodent studies)	Same
Contraindications	Personal/family history of MTC, MEN2	Same

The important takeaway: every clinical characteristic is identical. The differences are purely administrative — which condition it's prescribed for, how it's billed, and how insurance handles the claim.

FDA Approval History: How We Got Here

Understanding the timeline helps explain why doctors, patients, and insurance companies treat these two products differently despite being the same drug.

Mounjaro's Path (Type 2 Diabetes)

Eli Lilly's SURPASS clinical trial program studied tirzepatide in adults with type 2 diabetes across multiple large trials:

SURPASS-1 (2021): Tirzepatide as monotherapy reduced A1C by up to 2.07% from baseline and produced weight loss of up to 9.5 kg (about 21 pounds) over 40 weeks.
SURPASS-2 (2021): Compared directly to semaglutide 1 mg, tirzepatide 15 mg reduced A1C by 2.46% vs 1.86% for semaglutide — and 51% of patients on tirzepatide 15 mg achieved a normal A1C below 5.7%, compared to 20% on semaglutide.
SURPASS-3 (2021): Tirzepatide outperformed insulin degludec in A1C reduction and weight loss.
SURPASS-4 (2022): Tirzepatide was superior to insulin glargine in patients already on 1-3 oral diabetes medications.

Based on this data, the FDA approved Mounjaro in May 2022 for adults with type 2 diabetes as an adjunct to diet and exercise. Doctors could immediately prescribe it, and insurance companies began covering it under their diabetes drug formularies.

Zepbound's Path (Weight Management)

Even before Mounjaro launched, it was obvious the weight loss seen in diabetes trials was remarkable. But the FDA requires a separate approval process for weight management indications. Eli Lilly ran the SURMOUNT program specifically in people with obesity or overweight without type 2 diabetes:

SURMOUNT-1 (2022): Participants on tirzepatide 15 mg lost an average of 22.5% of body weight over 72 weeks — the largest weight reduction ever seen in a non-surgical obesity trial at the time. That translates to roughly 52 pounds for someone starting at 230 pounds.
SURMOUNT-2 (2023): Studied tirzepatide specifically in people with both obesity and type 2 diabetes. Even in this harder-to-treat population, patients lost up to 14.7% of body weight.
SURMOUNT-3 (2023): Showed tirzepatide maintained and extended weight loss even after an initial intensive lifestyle intervention phase.
SURMOUNT-4 (2023): A withdrawal design trial showing patients who stopped tirzepatide after 36 weeks regained a significant portion of their weight loss, while those who continued lost even more weight.

The FDA approved Zepbound in November 2023 based primarily on SURMOUNT-1 and SURMOUNT-2 data. In December 2024, the FDA expanded the indication to include treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.

Why This Matters for You

If you have type 2 diabetes, your doctor prescribes Mounjaro. If you have obesity without diabetes, your doctor prescribes Zepbound. Same drug, different prescription. But the label on the box determines everything about how you access and pay for the medication.

Insurance Coverage: Where the Real Difference Lives

This is where the two-brand system creates the most confusion — and the most frustration for patients. The identical molecule in the identical dose from the identical manufacturer can cost you $25 per month or $1,000+ per month depending entirely on which label is on the box and which diagnosis code your doctor writes on the prescription.

Commercial Insurance Coverage

For Mounjaro (diabetes indication): Most commercial insurance plans include Mounjaro on their formularies. Type 2 diabetes is universally recognized as a covered condition, and GLP-1 medications have become standard of care. Many plans place Mounjaro on a preferred tier, especially after Eli Lilly negotiated formulary positions with major pharmacy benefit managers (PBMs).

For Zepbound (weight management indication): Coverage is much more variable. As of early 2026, an estimated 40% of commercial insurance plans still exclude anti-obesity medications entirely. Even among plans that do cover weight-loss drugs, Zepbound may be on a non-preferred tier with higher copays, or it may require prior authorization with strict criteria (documented BMI, failed lifestyle interventions, comorbidities).

The good news: coverage for anti-obesity medications has been improving. Several major employers expanded coverage in 2025-2026 after studies demonstrated that GLP-1 medications reduce cardiovascular events, joint replacements, and other expensive medical costs downstream — making the initial drug cost a net positive for payers.

Medicare Coverage

This is the sharpest divide between the two brands.

Mounjaro: Covered under Part D. Medicare Part D covers diabetes medications, and Mounjaro is included in most Part D formularies. Patients with type 2 diabetes on Medicare can access Mounjaro, though copays vary based on the specific plan and formulary tier.

Zepbound: Not covered. Period. Under current federal law (the Medicare Modernization Act), Medicare is prohibited from covering drugs prescribed for weight loss. This exclusion applies to Zepbound, Wegovy, and every other medication used primarily for obesity treatment. Despite bipartisan legislative efforts — including the Treat and Reduce Obesity Act, which has been reintroduced in Congress multiple times — this exclusion remains in place as of April 2026.

This means a 67-year-old Medicare beneficiary with a BMI of 35 and sleep apnea, hypertension, and knee osteoarthritis cannot get Zepbound covered by Medicare, even though clinical evidence shows it would improve all of those conditions. If that same patient also has a type 2 diabetes diagnosis, they could get Mounjaro covered — same drug, same dose — because the label says "diabetes" instead of "weight loss."

For a full breakdown of savings options across all GLP-1 medications, read our GLP-1 savings programs and discounts guide.

Eli Lilly Savings Programs

Eli Lilly offers manufacturer savings cards for both brands:

Mounjaro Savings Card: Eligible commercially insured patients may pay as little as $25 per month for a 1-month supply (up to 12 fills). Patients without insurance or whose insurance doesn't cover Mounjaro may also qualify for savings.
Zepbound Savings Card: Similar structure — eligible patients with commercial insurance may pay as little as $25 per month. Lilly also launched a direct-to-patient program in late 2024 offering certain Zepbound doses at reduced prices for cash-pay patients.

These savings cards do not work with Medicare, Medicaid, Tricare, or other government-funded insurance programs.

Cost Breakdown: What You'll Actually Pay

Let's get specific about money — because "list price" and "what you actually pay" are very different numbers.

List Prices (Without Any Insurance or Discounts)

Dose	Mounjaro List Price	Zepbound List Price
2.5 mg (starter dose)	~$1,023/month	~$1,059/month
5 mg	~$1,023/month	~$1,059/month
7.5 mg	~$1,023/month	~$1,059/month
10 mg	~$1,023/month	~$1,059/month
12.5 mg	~$1,023/month	~$1,059/month
15 mg (max dose)	~$1,023/month	~$1,059/month

Pricing is the same across all dose strengths for each brand. Zepbound's list price runs about $36/month higher than Mounjaro's, though these numbers shift slightly with periodic adjustments.

Real-World Cost Scenarios

Scenario 1: Type 2 diabetes, commercial insurance, Mounjaro With a savings card and commercial insurance that covers Mounjaro: $25/month. This is the best-case scenario and what a large number of patients actually pay.

Scenario 2: Obesity (no diabetes), commercial insurance that covers weight-loss drugs, Zepbound With a savings card and a plan that includes anti-obesity medication coverage: $25/month. Same best case, but fewer patients qualify because fewer plans cover Zepbound.

Scenario 3: Obesity, commercial insurance that excludes weight-loss drugs Without coverage, the savings card alone won't bring costs to $25. Some patients in this category use Lilly's direct-to-patient programs and pay roughly $399–$549/month for certain doses — a significant discount from list price but still a substantial out-of-pocket expense.

Scenario 4: Medicare beneficiary with type 2 diabetes, Mounjaro Part D coverage kicks in, but copays depend on the plan tier and deductible status. Typical cost: $50–$300/month depending on the Part D plan. The manufacturer savings card cannot be used with Medicare.

Scenario 5: Medicare beneficiary with obesity (no diabetes), Zepbound Not covered. Full list price of ~$1,059/month or whatever cash-pay discount you can negotiate. Lilly's savings card is not available for government insurance beneficiaries.

For a broader comparison of GLP-1 medication costs, our guide on the cheapest GLP-1 options without insurance breaks down alternatives across all brands.

Clinical Effectiveness: Does the Label Change How Well It Works?

No. And this is worth stating clearly because patient forums are full of people asking whether Mounjaro "works better for blood sugar" and Zepbound "works better for weight loss." They don't. They are the same molecule doing the same thing in your body.

Weight Loss Results

The SURMOUNT-1 trial — which specifically enrolled people with obesity who did not have diabetes — produced the headline numbers most people associate with Zepbound:

5 mg dose: 15.0% average body weight loss at 72 weeks
10 mg dose: 19.5% average body weight loss
15 mg dose: 20.9% average body weight loss (roughly 52 pounds for a 250-pound person)

But the SURPASS trials for Mounjaro (in diabetes patients) also showed significant weight loss:

SURPASS-2: Up to 12.4 kg (27 pounds) weight loss at 40 weeks
SURPASS-4: Up to 11.7 kg (26 pounds) weight loss at 52 weeks

The weight-loss numbers are somewhat lower in the diabetes trials, but that's because diabetes patients tend to lose less weight on GLP-1 medications than people without diabetes — not because the drug works differently. A 2025 real-world study published in Diabetes, Obesity and Metabolism confirmed that in patients without diabetes, tirzepatide produced significantly greater weight loss. But in patients with diabetes, the difference between tirzepatide and semaglutide was not statistically significant.

Blood Sugar Control

If you have type 2 diabetes, tirzepatide — whether labeled Mounjaro or Zepbound — will lower your blood sugar. The SURPASS trials documented:

A1C reductions of 1.87% to 2.46% depending on the dose and comparator
51% of patients on the 15 mg dose achieved a normal A1C below 5.7% in SURPASS-2 — a rate that was previously unheard of for non-insulin medications
Superior A1C reduction compared to semaglutide, insulin degludec, and insulin glargine across multiple trials

Cardiovascular Benefits

Both brands carry the same cardiovascular profile. Tirzepatide has shown improvements in blood pressure, triglycerides, and other cardiovascular risk markers across trials. The SURPASS-CVOT trial is still ongoing and will provide definitive cardiovascular outcomes data, but early signals are positive and consistent with what's been observed with GLP-1 receptor agonists as a class.

Obstructive Sleep Apnea

In December 2024, the FDA added moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity as an indication for Zepbound. This was based on the SURMOUNT-OSA trials, which showed:

Patients on tirzepatide experienced approximately a 55-63% reduction in the apnea-hypopnea index (AHI), the standard measure of sleep apnea severity
Significant improvements in oxygen saturation during sleep
Reductions in daytime sleepiness scores

This indication was added to Zepbound (not Mounjaro), but the drug effect would be the same regardless of brand. If you have both type 2 diabetes and sleep apnea, your doctor would likely prescribe Mounjaro — the diabetes indication — and the sleep apnea would benefit regardless.

Side Effects: Identical Because It's the Same Drug

This section will be short because there is nothing to compare. Mounjaro and Zepbound cause the exact same side effects at the exact same rates because they are the same molecule at the same doses.

Common Side Effects (Reported in >5% of Clinical Trial Participants)

Nausea — the most common side effect, affecting roughly 15-25% of patients, typically worst during dose escalation and improving over time
Diarrhea — affects about 12-17% of patients
Vomiting — about 5-10% of patients
Constipation — about 6-11% of patients
Abdominal pain — about 5-8% of patients
Decreased appetite — about 5-10% of patients (this is partly how the drug works)
Injection site reactions — mild redness or swelling at the injection site

Serious Side Effects (Rare but Important)

Pancreatitis: Reported in clinical trials at low rates. Seek immediate medical attention for severe, persistent abdominal pain.
Gallbladder problems: Including gallstones and cholecystitis. Risk increases with rapid weight loss.
Hypoglycemia: More likely when combined with insulin or sulfonylureas. Less common when used alone.
Thyroid C-cell tumors: Observed in rodent studies. Both Mounjaro and Zepbound carry a black box warning about this risk. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
Severe gastrointestinal events: Gastroparesis (delayed stomach emptying) and intestinal obstruction have been reported, though uncommonly.

For a comprehensive look at what to expect, see our GLP-1 side effects complete guide.

Who Should Take Mounjaro vs Zepbound?

This is a prescribing decision your doctor makes based on your diagnosis — not a choice you make at the pharmacy counter. But understanding the framework helps you have a better conversation with your provider.

Mounjaro Is Prescribed When:

You have a confirmed diagnosis of type 2 diabetes
Your doctor wants to improve blood sugar control and/or promote weight loss
You may also have overweight or obesity, but the primary treatment target is diabetes
Your insurance covers diabetes medications (most do)

Zepbound Is Prescribed When:

You have a BMI of 30 or higher (obesity), OR a BMI of 27 or higher with at least one weight-related condition (hypertension, high cholesterol, cardiovascular disease, obstructive sleep apnea)
You do not have type 2 diabetes (or your doctor is specifically targeting weight management rather than diabetes)
Your insurance covers anti-obesity medications (check first — many plans don't)

The Gray Area: Off-Label Prescribing

Here's where things get complicated. Doctors can prescribe medications "off-label" — meaning for conditions not listed on the FDA-approved label. This is legal and common in medicine. Some doctors prescribe Mounjaro off-label for weight loss in patients without diabetes, particularly when the patient's insurance covers Mounjaro but not Zepbound.

Is this appropriate? It depends on who you ask. Clinically, the drug will have the same effect regardless of which label is on it. From a regulatory and insurance standpoint, prescribing Mounjaro for a patient who doesn't have diabetes could be considered off-label use, and insurance companies may audit claims where the drug doesn't match the diagnosis code.

Some patients also wonder about switching between brands. If you've been on Mounjaro for diabetes and your A1C has normalized, can you switch to Zepbound for continued weight management? Technically yes — it's the same drug — but the insurance implications change. Read our switching from Ozempic to Mounjaro guide for more on navigating these transitions, including dose equivalency and insurance considerations.

Starting Doses and Titration (Same for Both)

The dosing schedule is identical:

Weeks 1-4: 2.5 mg once weekly (starter dose, not intended as a therapeutic dose)
Weeks 5-8: 5 mg once weekly
After week 8: Increase in 2.5 mg increments every 4 weeks as tolerated
Maximum dose: 15 mg once weekly

Most patients find a therapeutic sweet spot between 7.5 mg and 15 mg. Your doctor adjusts based on your response, side effect tolerance, and treatment goals. Slower titration (staying at each dose for 8 weeks instead of 4) can reduce GI side effects.

Can You Switch Between Mounjaro and Zepbound?

Yes, without any medical concern — because it's the same drug. If your pharmacy has Zepbound 10 mg in stock but not Mounjaro 10 mg, and your doctor writes a new prescription for the available brand, you'd get the identical medication. No dose adjustment needed, no washout period, no transition protocol.

The reasons people switch between brands are almost always administrative:

Insurance change: Your new plan covers one brand but not the other
Formulary change: Your insurer moved one brand to a different tier or dropped it
Supply availability: During shortage periods (which have been less common in 2026 than in 2024), one brand may be more readily available
Diagnosis update: You developed type 2 diabetes and your doctor switched your prescription from Zepbound to Mounjaro to match the new diagnosis code
Cost optimization: One brand has a better savings program or copay structure for your situation

What About Supply and Availability?

In 2024, tirzepatide experienced significant supply constraints that affected both brands. Eli Lilly invested heavily in manufacturing expansion, and by mid-2025, supply had largely stabilized for most doses. As of early 2026, both Mounjaro and Zepbound are generally available across all dose strengths, though spot shortages of specific doses still occur occasionally at individual pharmacies.

If you experience availability issues, ask your pharmacist to check other nearby locations or contact Eli Lilly's Mounjaro or Zepbound support lines for help locating stock.

The Bigger Picture: Why Separate Brands Exist

The Mounjaro/Zepbound split isn't a cynical move by Eli Lilly. It's a structural consequence of how the U.S. healthcare system handles drug approvals, insurance billing, and reimbursement.

The Regulatory Logic

The FDA requires that each approved indication be backed by dedicated clinical evidence. You can't get an obesity approval based on diabetes trials alone — even if the weight-loss data is compelling. Eli Lilly had to invest billions in the SURMOUNT program specifically to prove tirzepatide's efficacy and safety as a weight-loss treatment. A separate brand name makes the distinction clear for prescribers, pharmacists, and payers.

The Insurance Logic

Insurance companies use drug billing codes (NDC numbers) to determine coverage. A single drug with two NDC codes — one linked to a diabetes indication, one to a weight-loss indication — allows payers to cover the one they want and exclude the other. Without separate brand names, insurers would have a harder time distinguishing between a diabetes prescription and a weight-loss prescription for the same molecule.

The Patient Impact

For patients, the dual-brand system creates confusion but also creates access pathways that might not otherwise exist. Before Zepbound's approval, patients seeking tirzepatide for weight loss had to rely on off-label Mounjaro prescriptions. Now there's an on-label option specifically for weight management, which:

Creates a clear clinical pathway for obesity treatment
Enables Eli Lilly to market directly to patients seeking weight loss (which they cannot do with Mounjaro's diabetes-only label)
Builds the evidence base for anti-obesity medications as a category, strengthening the argument for broader insurance coverage
Adds another data point for legislative efforts to expand Medicare coverage of obesity treatments

The downside is the coverage gap. The same person who would be fully covered taking tirzepatide for diabetes may face $12,000+ per year in out-of-pocket costs taking the identical drug for obesity. That gap reflects a policy problem, not a drug problem — and it's slowly narrowing as insurers recognize the long-term cost savings of treating obesity early.

For a broader view of how all GLP-1 medications compare for weight loss versus diabetes, check our best GLP-1 for weight loss vs diabetes guide.

Frequently Asked Questions

Is Mounjaro the exact same thing as Zepbound?

Yes. Both contain tirzepatide as the active ingredient, manufactured by Eli Lilly. They are molecularly identical — same chemical structure, same doses (2.5 mg through 15 mg), same injection pen design. The only differences are the brand name on the box, the FDA-approved indication (diabetes for Mounjaro, weight management for Zepbound), and the billing/insurance codes. If you took a dose of each at the same strength, your body would not be able to tell the difference.

Can my doctor prescribe Mounjaro for weight loss instead of Zepbound?

Doctors can legally prescribe medications off-label, meaning for conditions not on the FDA-approved label. Some doctors do prescribe Mounjaro off-label for weight loss, particularly when a patient's insurance covers Mounjaro but not Zepbound. However, insurance companies may reject the claim if the diagnosis code doesn't match the drug's approved indication, and some insurers audit for this. Discuss both options with your doctor and check your specific insurance formulary before filling the prescription.

Why is Zepbound not covered by Medicare when Mounjaro is?

Federal law (specifically the Medicare Modernization Act of 2003) prohibits Medicare Part D from covering drugs used for "anorexia, weight loss, or weight gain." This exclusion applies to all anti-obesity medications, including Zepbound, Wegovy, and Saxenda. Mounjaro is covered because its approved indication is type 2 diabetes, which is a covered condition. Multiple bills have been introduced in Congress to remove this exclusion — including the Treat and Reduce Obesity Act — but none have passed as of April 2026.

If I switch from Mounjaro to Zepbound (or vice versa), do I need to change my dose?

No. Because they are the same drug at the same available doses, you continue at whatever dose you were taking. If you were on Mounjaro 10 mg, you'd take Zepbound 10 mg — no titration adjustment needed, no washout period. The only things that change are the brand name on the prescription, the billing code, and potentially your copay.

Which one produces more weight loss — Mounjaro or Zepbound?

Neither. They produce identical weight loss because they are identical drugs. The clinical trial results differ slightly because they studied different patient populations — the SURMOUNT trials (Zepbound) enrolled people with obesity but without diabetes, while the SURPASS trials (Mounjaro) enrolled people with type 2 diabetes. People without diabetes tend to lose more weight on GLP-1 medications than people with diabetes, so the SURMOUNT results show higher percentage weight loss. But if you gave Mounjaro and Zepbound to the same person at the same dose, the results would be the same.

Quick Answer